Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables Refunds
Ratios

Universe Pharmaceuticals (UPC) Accumulated Depreciation & Amortization (2021 - 2025)

Universe Pharmaceuticals' Accumulated Depreciation & Amortization history spans 5 years, with the latest figure at $6.9 billion for Q3 2025.

  • For Q3 2025, Accumulated Depreciation & Amortization rose 3.59% year-over-year to $6.9 billion; the TTM value through Sep 2025 reached $6.9 billion, up 3.59%, while the annual FY2025 figure was $6.9 billion, 3.59% up from the prior year.
  • Accumulated Depreciation & Amortization for Q3 2025 was $6.9 billion at Universe Pharmaceuticals, up from $6.7 billion in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $6.9 billion in Q3 2025 and bottomed at $5.7 million in Q3 2022.
  • The 5-year median for Accumulated Depreciation & Amortization is $6.1 million (2023), against an average of $2.7 billion.
  • The largest annual shift saw Accumulated Depreciation & Amortization fell 1.21% in 2022 before it soared 110052.67% in 2024.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $5.8 million in 2021, then dropped by 1.21% to $5.7 million in 2022, then grew by 5.96% to $6.1 million in 2023, then skyrocketed by 110052.67% to $6.7 billion in 2024, then rose by 3.59% to $6.9 billion in 2025.
  • Per Business Quant, the three most recent readings for UPC's Accumulated Depreciation & Amortization are $6.9 billion (Q3 2025), $6.7 billion (Q3 2024), and $6.1 million (Q3 2023).